Albany, NY -- (SBWIRE) -- 12/29/2015 -- A global surge in diabetic population, coupled with technological innovations and extensive R&D activities, has boosted the worldwide market for diabetes devices and drugs, according to a report published by Transparency Market Research.The report, titled "Diabetes Devices and Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019", indicates that registering a CAGR of 5.9% from 2013 to 2019, the global diabetes devices and drugs market is likely to grow from US$54.04 billion in 2012 to US$83.0 billion in 2019.The diabetes devices market is bifurcated into insulin delivery devices and diabetes monitoring and diagnostic devices. The major diabetes monitoring and diagnostic devices include glucose test strips, analog glucose meter, continuous glucose monitoring devices, and lancets and lancing devices. By the end of 2019, test strips are anticipated to be the leading segment while continuous glucose monitoring devices will be the most rapidly growing segment. Insulin delivery devices include insulin pens, insulin pumps, insulin syringes, and insulin injectors. Insulin pens, followed by syringes, formed the largest segments in 2012.

Browse the full Diabetes Devices and Drugs Market (Devices: Diagnostic & Monitoring and Insulin Delivery Devices, Drugs: Insulin Derivatives, GLP-1 and OADs) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 report at http://www.transparencymarketresearch.com/diabetes-devices-market.html

On the basis of therapy, the diabetes drugs market is segmented into oral anti-diabetes drugs class, insulin, and non-insulin injectable anti-diabetes drugs. The various insulin derivatives include premixed insulin, rapid-acting insulin, short-acting insulin, long-acting insulin, and intermediate-acting insulin. With a 42.77% share, long-acting insulin derivatives held the majority in 2012 and are expected to record the highest CAGR by 2019. The oral anti-diabetes drugs class comprises Thiazolidinediones, SGLT-2 inhibitors, Sulphonylureas, DPP-4 inhibitors, Meglitinides, Biguanides, and Alpha-glucosidase inhibitors. Registering an impressive CAGR of 76.8% from 2013 to 2019, SGLT-2 inhibitors are expected to form the fastest growing segment. Non-insulin injectable anti-diabetes drugs include GLP-1 analogs, which are also anticipated to develop at a strong pace over the course of the forecast period.

The global diabetes devices and drugs market covers four key regions: North America, Europe, Asia Pacific, and Rest of the World. Rise in diabetic population and growing demand for technologically-advanced devices and high-quality drugs has made North America the leading market for diabetes devices and drugs. However, Asia Pacific has been identified as the fastest developing regional segment from 2013 to 2019. This market is fueled by rise in diabetic population, increasing awareness about the management and self-monitoring of diabetes, hike in medical expenditure, and growing penetration of healthcare technology.

Get Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=14

The competitive landscape of the global diabetes devices and drugs market consists of numerous small and large players. Some of the dominating participants of the diabetes devices and drugs market are AstraZeneca plc, DexCom, Inc., Johnson & Johnson, Becton, Dickinson & Company, Merck & Co., Inc., Eli Lilly and Company, Bayer HealthCare AG, Lupin Limited, B. Braun Melsungen AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim GmbH, Novartis International AG, Takeda Pharmaceutical Company Limited, Sanofi, Abbott Laboratories, Inc., Medtronic, Inc., and Novo Nordisk A/S.

Read Full Press Release: http://www.transparencymarketresearch.com/pressrelease/global-diabetes-devices-market.htm

Global Diabetes Devices Market, by Devices
Diabetes Monitoring and diagnostic devices
Analog glucose meter
Glucose Test strips
Lancets and Lancing devices
Continuous glucose monitoring devices
Others
Insulin Delivery Devices
Insulin Syringes
Insulin Pens
Insulin Pumps
Insulin Injectors
Global Diabetes Drugs Market, by Therapy
Insulin
Short-acting insulin derivatives
Intermediate-acting insulin derivatives
Long-acting insulin derivatives
Rapid-acting insulin derivatives
Premixed insulin derivatives
Oral anti-diabetes drugs class
Sulphonylureas
Biguanides
Meglitinides
Thiazolidinediones
Alpha-glucosidase inhibitors
DPP-4 inhibitors
SGLT-2 inhibitors
Non-insulin injectable anti-diabetes drugs
GLP-1 analogs
Global Diabetes Drugs Market, by Geography
North America
Europe
Asia-Pacific
Rest of the World (RoW)

About Transparency Market Research (TMR)
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/